nAMD: Choosing the Best Treatment for your Patient

Prevalence of nAMD

Currently Available Anti-VEGF Therapies Used to Treat nAMD

The Use of Anti-VEGF Regimens

12-Month Mean Visual Acuity Outcomes by Treatment Regimen

How Much Has Treatment Evolved Since MARINA and ANCHOR Trials?

PRN Method: Benefits and Limitations

HARBOR Study Results

Dosing Regimens in VIEW 1/2 Through 96 Weeks

HARBOR Study: Number of Injections

AURA Study

AURA Study: Mean Visual Acuity Over 2 Years in Patients Treated With Ranibizumab

Undertreatment of Patients

LUMINOUS Study

Visual Acuity Gains Over 1 Year in Treatment-Naive Patients

Visual Acuity Stratified by Injection Frequency and Loading Dose

PRN vs Treat and Extend

Transition to Treat and Extend

Fight Retinal Blindness Registry: Baseline to 7 Years Using Treat and Extend Regimen

Consensus on Use of Treatment Approaches

Consensus on Use of Treatment Approaches (cont)

Management of Bilateral Disease

Use of Bilateral Simultaneous Treatment in Practice

Patient Compliance

Optimal Retreatment Interval

Long-Term Studies: Take Home Messages

Long-Term Causes of Progressive Vision Loss

Managing Poor Responders

Concluding Remarks

Concluding Remarks (cont)

Abbreviations

Abbreviations